Integrin beta-5 Antibodies

Integrin beta-5 (ITGB5)

Integrin alpha-V/beta-5 (ITGAV:ITGB5) is a receptor for fibronectin. It recognizes the sequence R-G-D in its ligand.

.

Gene Information

Human
Gene Name:	ITGB5
Uniprot:	P18084
Entrez:	3693

Family

Belongs to:
integrin beta chain family

Alternative Names

FLJ26658; Integrin beta 5; integrin beta-5; integrin, beta 5; ITGB5

Molecular Weight

Mass (kDA):
88.054 kDA

Genomic Context

Human
Location:	3q21.2
Sequence:	3; NC_000003.12 (124761948..124901411, complement)

Subcellular Localizations

Membrane; Single-pass type I membrane protein.

Diseases

• Tissue Adhesions
• Malignant Neoplasms
• Neoplasms
• Neoplasm Metastasis
• Malignant Paraganglionic Neoplasm
• Endometrial Polyp
• Malignant Neoplasm Of Stomach
• Stomach Neoplasms
• Tumor Angiogenesis
• Myeloid Leukemia
• Cell Invasion
• Cell Transformation, Neoplastic
• Leukemia

• Cholangiocarcinoma
• Prion Diseases
• Malignant Neoplasm Of Tongue
• Metastatic Malignant Neoplasm To The Lymph Node
• Malignant Neoplasm Of Breast
• Swine Diseases
• Hypoxia

Interacting Proteins

• ANGPTL4
• FRMD5
• ITGAV
• MYO10
• Myo7a

Pathways

• Reverse Transcription
• Cell Cycle
• Angiogenesis
• Pathogenesis
• Secretion
• Cell Adhesion
• Cell Migration
• Cell Proliferation
• Mitosis
• Immune Response
• Endothelial Cell Migration

• Dna Replication
• Embryo Implantation
• Integrin Activation
• Focal Adhesion Assembly
• Contact Inhibition
• Autophagy

PTMs

• Phosphorylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/ITGB5

Boster Bio Anti-Integrin Beta 5 Marker - What Are The Best Uses Of The ITGB5 Marker?

You've probably seen the name Boster Bio Anti-Integrin beta 5 (ITGB5 Marker) in a lab somewhere. What's the product all about? What are its applications? How accurate is it? What about safety? These are just some of the questions we'll answer below. We hope this information will help you decide if Boster Bio Anti-Integrin beta 5 is right for you.

Boster Bio Anti-Integrin beta 5/ITGB5 Marker

The Boster Bio Anti-Integrin Beta 5/ITGB5 Marker is a highly specific monoclonal antibody that binds to a specific epitope on integrin alpha-V subunit proteins. The antigens are found in every cell of the body and are integral cell-surface receptors. They are involved in cell adhesion and cell-surface-mediated signaling.

ITGB5 is an integrin-related protein that is expressed on many human tissues and cancers. It plays a role in the epithelial-mesenchymal transition and is expressed on both tumors and normal tissue. The role of ITGB5 in the tumor microenvironment is currently not fully understood. However, its role in cancer progression is known to be important.

ITGB5 is an intercellular signal transduction protein that may play a role in the progression of glioma. The study results suggest that ITGB5 is a possible therapeutic target in GBM. Furthermore, it may improve prognosis and monitor the response to standard radiotherapy and chemotherapy. ITGB5 is associated with cancer stem cell migration and invasion and is also involved in the formation of tubes by endothelial cells.

The Human Integrin beta 5 antibody detects this protein in Western blots and direct ELISAs. It has less than 5% cross-reactivity with other recombinant proteins. Different laboratories must determine optimal dilutions for specific applications. General protocols are available for determining the correct dilutions. This antibody should be used in conjunction with a corresponding polyclonal anti-Human Integrin beta 5/ITGB5 marker.

Applications

In the last few years, the ITGB5 gene has been identified in several human cancers. It regulates cell migration and invasion by facilitating the TGF-b-induced epithelial-mesenchymal transition. ITGB5 expression was recently found to be correlated with liver tropism in several malignancies. Nevertheless, the role of the ITGB5 gene in HCC is not well understood.

The ITGB5 gene belongs to the integrin family. It participates in adhesion of immune cells and is typically expressed as a dimer. ITGB5 preferentially binds to extracellular matrix and cellular adhesion molecules. ITGB5 is highly expressed in the lung and spleen, while low levels are found in the small intestine. The ITGB5 gene participates in numerous biological processes and functions, including cell migration and variation.

It has been found that knocking down the ITGB5 gene inhibits HCC cell migration. This suggests that ITGB5 may be a novel biomarker for HCC. Furthermore, it may be a useful therapeutic target in the treatment of HCC. It is a promising candidate for treatment in HCC, particularly in patients who have already had invasive surgeries. And because of its involvement in the development of tumors, it may be useful in detecting cancer before it progresses.

Studies have also found that the ITGAV/ITGB3 heterodimer is involved in tumor neoangiogenesis. The ITGAV/ITGB3 receptor is also implicated in tumor cell proliferation. Furthermore, both the ITGA5 and ITGAV heterodimer play important roles in metastasis. Among these, ITGA5 is associated with a strong pro-angiogenic response.

Validation

The validation of the ITGB5 marker for GBM and its function are inconclusive at present. However, it does demonstrate significant differences between low-grade and high-grade glioma. The elevated expression of ITGB5 in GBM is associated with poor survival in patients. This gene is involved in angiogenesis and regulation of the immune response in GBM. It is also required for migration and invasion of glioma cells.

The ITGB5 gene was obtained from Genecopeia, Inc. ITGB5 cDNA was transfected into HEK 293 T cells. These cells were cultured on a 6 cm dish. Transfections were performed using a combination of 2 mg pCDH-ITGB5 with 1.5 mg psPax2 and 0.5 mg pMD2G. After transfection, cells were subjected to a five-minute centrifugation. Puromycin was used as a selection marker.

Immunohistochemical and western blotting were used to determine the expression of ITGB5 in GBM. The study showed a significant correlation between ITGB5 and overall survival in patients with GBM. The findings indicated that ITGB5 can be used as a prognostic biomarker in GBM and to monitor the response of patients to standard chemotherapy and radiotherapy. Further research is required to identify which mutations of ITGB5 are associated with poorer outcome.

Moreover, knockdown of ITGB5 in Huh-7 and MHCC-97 L cells showed significant ITGB5 knockdown. Further, these stable cell lines expressed shRNA showed reduced colony formation relative to controls. Furthermore, the cells inhibited migration by ITGB5 knockdown in transwell assays. This result suggests that ITGB5 is a promising specific target for HCC therapy. This finding has further implications for the development of targeted therapies.

The ITGB5 gene expression was detected using miR-185 inhibitor. MiR-185 mimics reduced the expression of ITGB5 and b-catenin. When miR-185 was inhibited in mice, luciferase activity increased. However, miR-185 inhibitors increased the expression of ITGB5 and b-catenin. This suggested that miR-185 regulates the activity of ITGB5 and b-catenin.

Safety

The ITGB5 marker is a candidate for therapeutic use in glioma. It influences migration of glioma cells and controls the immune response and angiogenesis. Consequently, it is a potentially useful prognostic marker. The current study was carried out by PC, QG and AW. All authors read and approved the final manuscript. They acknowledge the support of the National Cancer Institute.

The markers identified by ITGB5 interaction with immune, inflammatory, vascular endothelial, and fibroblast populations in the GBM microenvironment. MCP-counter was used to quantify ITGB5 expression. Cell adhesion, vascular endothelial growth factor signaling, and NK cell numbers were positively associated with ITGB5 expression. However, the mechanisms by which ITGB5 regulates GC remain unknown.

In the present study, ITGB5 was correlated with immune infiltrates in the GC and with chemotherapeutic agents. Nevertheless, it is not clear whether ITGB5 expression correlates with a poor prognosis in GC. Furthermore, further research is needed to determine if ITGB5 serves as a potential target for precision therapy against GC. These findings suggest that ITGB5 may be a potential target for GC precision therapy.

The safety of the ITGB5 marker is not clear, but the results of clinical trials suggest that the marker may help detect early-stage cancers, which may be the result of a tumor that has spread to nearby tissues. Moreover, ITGB5 has also been positively associated with other genes in RNAseq datasets. However, further research is needed to determine whether ITGB5 is a reliable biomarker in predicting the prognosis of GC.

The study included the use of non-ECM primary antibodies DO-7 and clone 124, as well as EGFR-25, MMP-9, and ITGA-3. The ITGB5 marker showed the most differences in expression between GBM and LGG. Therefore, the marker may be a good candidate for glioma treatment. Therefore, the ITGB5 marker is an important tool for detecting cancer cells.

Moreover, ITGB5 inhibits the formation of tubes in glioma cells. Furthermore, ITGB5 is required for angiogenesis. Moreover, it may be released by extracellular vesicles. Moreover, the ITGB5 marker has been associated with a positive outcome in GC patients. This is an encouraging finding. If you want to know more about this marker, visit our website.